Skip to main content
Erschienen in: Current Treatment Options in Cardiovascular Medicine 4/2017

01.04.2017 | Heart Failure (W Tang, Section Editor)

Targeting Frailty in Heart Failure

verfasst von: Susan M. Joseph, MD, Michael W. Rich, MD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Opinion statement

Frailty is a systemic syndrome characterized by impaired physiologic reserve, slowness, weakness, and wasting. It is associated with, but distinct from, aging, disability, and multimorbidity. Frailty is extremely common in patients with heart failure and portends a worse prognosis. The two syndromes worsen one another via complex molecular and cellular mechanisms which are not fully understood but include increased levels of stress hormones and cytokines. In this article, we discuss the mechanisms of frailty and review common frailty metrics. We review and summarize the literature on the impact of frailty in heart failure and discuss treatment and management options.
Literatur
3.
Zurück zum Zitat Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683–93.CrossRefPubMed Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683–93.CrossRefPubMed
4.
Zurück zum Zitat • Flint KM, Matlock DD, Lindenfeld J, Allen LA. Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail. 2012 Mar 1;5(2):286-93. This paper gives a great framework on the complexities in decision making when assessing patients for DT-LVAD for the frailty syndrome and provides a comprehensive review of the medical literature. • Flint KM, Matlock DD, Lindenfeld J, Allen LA. Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail. 2012 Mar 1;5(2):286-93. This paper gives a great framework on the complexities in decision making when assessing patients for DT-LVAD for the frailty syndrome and provides a comprehensive review of the medical literature.
6.
Zurück zum Zitat De Vries NM, Staal JB, Van Ravensberg CD, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2010;10:104–14.CrossRefPubMed De Vries NM, Staal JB, Van Ravensberg CD, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2010;10:104–14.CrossRefPubMed
9.
Zurück zum Zitat Dunlay SM, Park SJ, Joyce LD, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Hear Lung Transplant. 2014;33:359–65.CrossRef Dunlay SM, Park SJ, Joyce LD, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Hear Lung Transplant. 2014;33:359–65.CrossRef
10.
Zurück zum Zitat Heberton GA, Nassif M, Bierhals A, Novak E, Larue SJ, et al. Usefulness of psoas muscle area determined by computed tomography to predict mortality or prolonged length of hospital stay in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2016 [cited 2016 Nov 1];118(9):1363-7. Heberton GA, Nassif M, Bierhals A, Novak E, Larue SJ, et al. Usefulness of psoas muscle area determined by computed tomography to predict mortality or prolonged length of hospital stay in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2016 [cited 2016 Nov 1];118(9):1363-7.
14.
Zurück zum Zitat Sheetz KH, Zhao L, Holcombe SA, et al. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus. 2013;26:716–22.PubMedPubMedCentral Sheetz KH, Zhao L, Holcombe SA, et al. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus. 2013;26:716–22.PubMedPubMedCentral
15.
Zurück zum Zitat Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, et al. The impact of frailty in older patients with non-ischaemic cardiomyopathy after implantation of cardiac resynchronization therapy defibrillator. Europace. 2015;17:598–602.CrossRefPubMed Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, et al. The impact of frailty in older patients with non-ischaemic cardiomyopathy after implantation of cardiac resynchronization therapy defibrillator. Europace. 2015;17:598–602.CrossRefPubMed
16.
Zurück zum Zitat Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. 2014. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. 2014.
20.
Zurück zum Zitat Cacciatore F, Abete P, Mazzella F, et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest. 2005;35:723–30.CrossRefPubMed Cacciatore F, Abete P, Mazzella F, et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest. 2005;35:723–30.CrossRefPubMed
22.
Zurück zum Zitat Madan SA, Fida N, Barman P, et al. Frailty assessment in advanced heart failure. J Card Fail. 2016;22:840–4.CrossRefPubMed Madan SA, Fida N, Barman P, et al. Frailty assessment in advanced heart failure. J Card Fail. 2016;22:840–4.CrossRefPubMed
24.
Zurück zum Zitat Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009;103:1616–21.CrossRefPubMed Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009;103:1616–21.CrossRefPubMed
29.
Zurück zum Zitat Kirklin JK, Naftel DC, Kormos RL, et al. The fourth INTERMACS annual report: 4,000 implants and counting. J Hear Lung Transplant. 2012;31:117–26.CrossRef Kirklin JK, Naftel DC, Kormos RL, et al. The fourth INTERMACS annual report: 4,000 implants and counting. J Hear Lung Transplant. 2012;31:117–26.CrossRef
30.
Zurück zum Zitat Matthews JC, Pagani FD, Haft JW, et al. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation. 2010;121:214–20.CrossRefPubMedPubMedCentral Matthews JC, Pagani FD, Haft JW, et al. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation. 2010;121:214–20.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices the HeartMate II risk score. 2013. Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices the HeartMate II risk score. 2013.
32.
Zurück zum Zitat Chung CJ, Wu C, Jones M, et al. Reduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placement. 2014. Chung CJ, Wu C, Jones M, et al. Reduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placement. 2014.
33.
Zurück zum Zitat Jha SR, Med Sci B, Hannu MK, et al. The prevalence and prognostic significance of frailty in patients with advanced heart failure referred for heart transplantation. Transplantation. 2016;100:429–36.CrossRefPubMed Jha SR, Med Sci B, Hannu MK, et al. The prevalence and prognostic significance of frailty in patients with advanced heart failure referred for heart transplantation. Transplantation. 2016;100:429–36.CrossRefPubMed
36.
Zurück zum Zitat Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD003331. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD003331.
37.
39.
40.
Zurück zum Zitat Morley MBJE, Vellas B, Abellan van Kan G, et al. Frailty consensus: a call to action. 2013. Morley MBJE, Vellas B, Abellan van Kan G, et al. Frailty consensus: a call to action. 2013.
44.
Zurück zum Zitat Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, et al. Testosterone supplementation in heart failure clinical perspective. Circ Hear Fail. 2012 May 1;5(3):315-21. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, et al. Testosterone supplementation in heart failure clinical perspective. Circ Hear Fail. 2012 May 1;5(3):315-21.
47.
Zurück zum Zitat Vidán MT, Blaya-Novakova V, Sánchez E, Ortiz J, Serra-Rexach JA, et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail [Internet]. 2016 [cited 2016 Nov 19];18:869–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27072307 Vidán MT, Blaya-Novakova V, Sánchez E, Ortiz J, Serra-Rexach JA, et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail [Internet]. 2016 [cited 2016 Nov 19];18:869–75. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27072307
Metadaten
Titel
Targeting Frailty in Heart Failure
verfasst von
Susan M. Joseph, MD
Michael W. Rich, MD
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 4/2017
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-017-0527-5

Weitere Artikel der Ausgabe 4/2017

Current Treatment Options in Cardiovascular Medicine 4/2017 Zur Ausgabe

Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

Vascular Disease (I Weinberg, Section Editor)

Novel and Advanced Techniques for Complex IVC Filter Retrieval

Heart Failure (W Tang, Section Editor)

Targeting the Microbiome in Heart Failure

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Management of Percutaneous Coronary Intervention Complications

Vascular Disease (I Weinberg, Section Editor)

Acute Aortic Syndromes: Update in Current Medical Management

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.